Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shuangshen Sanjie Formula is a Traditional Chinese Medicine (TCM) herbal composition developed by Guang'anmen Hospital of the China Academy of Chinese Medical Sciences. It is specifically designed for the treatment and prevention of postoperative recurrence in patients with glioblastoma. The formula follows TCM principles aimed at "strengthening the body's resistance" (Fuzheng) and "dissipating masses" (Sanjie). It is currently being evaluated in clinical trials as an adjuvant therapy to standard postoperative treatments, such as radiotherapy and temozolomide, with the goal of extending disease-free survival (DFS) and overall survival (OS) while improving the quality of life for patients with high-grade gliomas.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shuangshen Sanjie Formula.